Compare Ascendis Pharma A/S (ASND) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Caesars Entertainment Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Caesars Entertainment Inc trades at $29.86 (market cap $6.08B). The key difference: Ascendis Pharma A/S is far larger — about 2.9× Caesars Entertainment Inc's market cap. Which is the better fit depends on your goals.
| ASND | CZR | |
|---|---|---|
Market Cap | $17.74B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $30.84 |
52-Week Low | $163.32 | $18.14 |
Enterprise Value | $18.11B | $30.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CZR trades at $29.84, up 0.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $31.27. The company reported Q1 2026 EPS of -$0.48, missing expectations, and has a negative net income margin of -4.19%. Recent news highlights the pending acquisition by Fertitta Entertainment and the opening of Caesars Republic Lake Tahoe.
CZR faces headwinds from recent earnings misses and negative profitability, but the acquisition offer and improving cash flow trends provide upside potential. Risks include high debt levels and competitive pressures in the leisure sector. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
